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Abstract 42 
Background: Vitamin D deficiency is a global problem that may be improved by vitamin D 43 
supplementation; however, the individual's response to the intervention varies. We aimed to 44 
investigate possible genetic factors that may modify the impact of environmental exposure on 45 
vitamin D status. The candidate gene variant we investigated was the Gc gene-rs4588 46 
polymorphism at the vitamin D receptor (DBP) locus. 47 
Methods: A total of 619 healthy adolescent Iranian girls received 50000 IU of vitamin D3 48 
weekly for 9 weeks. Serum 25(OH) D concentrations, metabolic profiles and dietary intake 49 
were measured at baseline and after 9 weeks of supplementation. The genotypes of the DBP 50 
variant (rs4588) were analyzed using the TaqMan genotyping assay. 51 
Results: Our results revealed that the rs4588 polymorphism might be associated with serum 52 
25-hydroxy vitamin D both at baseline (p value=0.03) and after intervention (p value=0.008). 53 
It seemed that the outcome of the intervention was gene-related so that the subjects with 54 
common AA genotype were a better responder to vitamin D supplementation (Changes (%) 55 
469.5(427.1) in AA carriers vs. 335.8(530) in GG holders), and carriers of the less common 56 
GG genotype experienced a rise in blood glucose after 9 weeks (Changes (%) 0 (1.5)). Our 57 
findings also showed that the statistical interaction between this variant and supplementation 58 
was statistically significant (intervention effect p-value<0.001 and p-value SNP effect=0.03). 59 
The regression model also revealed that after adjusted for potential confounders, likelihood of 60 
affecting serum 25(OH)D in individuals who were homozygous for the uncommon allele G 61 
was less than those homozygous for the more common AA genotype (OR=4.407 (1.82-8.89); 62 
p=0.001).  63 
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Conclusion: Serum vitamin 25(OH) D following vitamin 25(OH) D3 supplementation 64 
appears to be modified by genetic background. The Gc genetic variant, rs4588 encoding the 65 
vitamin D receptor seems to influence the response to vitamin D supplementation.  66 
Key words: Total 25(OH) D, Supplementation, Gc gene, rs4588. 67 
Introduction 68 
In addition to its classical functions in bone and mineral metabolism, vitamin D has several 69 
roles in the human body including modulation cell proliferation, differentiation, apoptosis 70 
and immune function. Growing body of evidence has revealed associations between vitamin 71 
D deficiency and several health outcomes. The vitamin D receptor is expressed in numerous 72 
tissues [1], and there is a relationship between low serum 25(OH)D  levels and risk of chronic 73 
diseases including cardiovascular disease, diabetes, and cancer [2]. The major sources of 74 
vitamin D in humans are dermal synthesis with U.V. exposure and dietary intakes such as 75 
oily fish and dairy products. Therefore, subjects with vitamin D deficiency need 76 
supplementation if the deficiency cannot be adequately corrected by changes in lifestyle such 77 
as more outdoor activities or a vitamin D rich diet. However, it has been shown that the 78 
serum 25(OH)D level also depends on the interaction between environmental and genetic 79 
factors [3, 4]. Several family and twin studies investigated the contribution of genetic 80 
background in association with variance in serum vitamin D, estimating heritability of serum 81 
vitamin D vary between 23% and 80 %[5].Various SNPs affect the serum 25(OH) D levels 82 
produced by the skin or received from the diet, it seems that they could also influence serum 83 
25(OH) D level following supplementation. If so, it might be necessary to take genetic factors 84 
into account when recommending vitamin D supplementation.  85 
The vitamin D binding protein (DBP), originally known as the group-specific component 86 
(Gc-globulin), is a multifunctional protein in an ascetic fluid, plasma, the cerebrospinal fluid 87 
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that also found on the surface of numerous cells. It binds to the different forms of vitamin D 88 
(ergocalciferol (D2) and cholecalciferol (D3), the 25-hydroxylated forms (calcifediol, and the 89 
active product, 1,25-dihydroxy vitamin D (calcitriol)). In the human body, the DBP is the 90 
major blood transporter of vitamin D [6] and is also a Macrophage Activating Factor (MAF) 91 
that has been a target for cancer treatments [7]. The main genetic variations (Gc1S,  Gc1F 92 
and  Gc2) are associated with differences in circulating 25(OH) D3  levels [3]. It appears that 93 
they may be determinants of vitamin D status in different genetic backgrounds [8]; moreover, 94 
several studies have shown a relationship between these variants and the response to vitamin 95 
D supplementation[9-11]. In addition, recently emerging evidence from gene-diet interaction 96 
analyses in large-scale observational studies and randomized intervention trials favour the 97 
idea that complex diseases may be due to interactions between lifestyle (e.g. diet) and genetic 98 
make-up [12]. However, this field is in its infancy and supporting data are still sparse; and 99 
little of the knowledge about gene-diet interaction has been applied in public health practice. 100 
The aim of the present study was to evaluate the influence of DBP variants on responding to 101 
vitamin D3 supplementation  102 
Material and method 103 
The 619 girls aged 12-17 years old were recruited between January and April 2015 in 104 
Mashhad city, by a randomized cluster sampling method. Informed consent was collected 105 
from all participants using protocols approved by the Ethics Committee of the Mashhad 106 
University of Medical Sciences. Participants with chronic diseases history, or who were 107 
taking any kinds of dietary supplements and anti-depressant or psychotropic drugs were 108 
excluded from the study. Subjects received 50,000 IU vitamin D3/week over 9 weeks. The 109 
total 25(OH) D in serum and metabolic profiles were measured at the baseline and after 110 
the intervention (fig.1).  111 
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Anthropometric and biochemical measurements 112 
Anthropometric parameters (e.g., height, body weight) and blood pressure were measured by 113 
trained technicians in both phases.  With the metric system, the formula for BMI is weight in 114 
kilograms divided by height in meters squared. Weight and Height were measured by 115 
standardized procedures. A portable stadiometer was used so as to measure height (OTM, 116 
Tehran, Iran), being taken to the nearest 0.1 cm, no shoes, subjects stretching to the 117 
maximum height while the head positioned in the Frankfort line. For weight measuring, 118 
Rassa weight scale (Rassa, Tehran, Iran) was used to the nearest 100 gram while subjects had 119 
no shoes and wore light clothes.  120 
Biochemical markers including serum high sensitivity C-reactive protein (Hs-CRP), fasting 121 
blood glucose (FBG) and lipid profile; total cholesterol (TC), triglyceride (TG), high-density 122 
lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C) were 123 
evaluated as described previously[13, 14]. The total serum 25(OH) vitamin D level (the sum 124 
of 25OHD2 and 25OHD3) was determined using an electrochemiluminescence method 125 
(ECL, Roche, Basel, Switzerland). Subjects were categorized based on serum 25(OH)D into 126 
3 groups: Deficient group: Serum 25(OH)D level<50nmol/L; Sufficient group: 50nmol/L  to 127 
<75nmol/L; Desirable one >75nmol/L[15].  128 
Dietary and physical activity assessment 129 
We used a validated food frequency questionnaire in order to assess dietary intakes [16]. To 130 
analysis energy and other nutrient intakes, we converted the reported portion size in FFQ to 131 
grams using household measures and then were introduced to the Nutritionist IV software. 132 
Moreover, the level of physical activity was studied by a validated questionnaire [16] and 133 
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reported as metabolic equivalents (METs) in hours per day. Demographic data, sun exposure 134 
and use of sunscreen were collected by an expert interviewer and by the use of a standard 135 
questionnaire[17].  136 
DNA extraction and genotyping 137 
Genomic DNA was extracted from EDTA blood samples using QIAamp® DNA Mini-Kit 138 
(Qiagen, San Diego, CA) according to the manufacturer's instructions. The purity and 139 
concentration of DNA samples were determined using the NanoDrop®-1000-Detector 140 
(NanoDrop-Technologies, Wilmington, USA). Genotype analysis of CYP2R1-rs10766197 141 
polymorphism was carried out using Taq-man®-probes-based assay; PCR reactions were 142 
performed in 12.5 ml total volume, using 20 ng of DNA in TaqMan®n Universal MasterMix 143 
with specific primers and probes (Applied Biosystems Foster City, CA). To assess the allelic 144 
content, an ABIPRISM-7500 instrument equipped with the SDS version-2.0 software was 145 
used.  146 
Statistical analysis 147 
Data was analyzed using SPSS version 20, IBM (SPSS Inc., IL, USA). Variables are reported 148 
as the mean ± standard deviation (SD). Continuous variables were analyzed for normality 149 
using the Kolmogorov–Smirnov test. Analysis of variance (ANOVA) was performed to 150 
compare changes in biomarkers after intervention in different genotype groups. Post hoc 151 
analysis was done using Tukey’s test. A Chi-square test with continuity correction was used 152 
to determine whether genotype frequencies followed the Hardy–Weinberg Equilibrium. 153 
Repeated measures analysis of covariance (ANCOVA) was performed to investigate the 154 
effect of the genotypes. Logistic regression also was performed to study the probability of 155 
change in serum 25(OH) D in different genetic models. For dietary analysis, all dietary 156 
variables were adjusted for the total energy intake using a residual model [32]. We 157 
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considered age, BMI, physical activity, sun exposure, and passive smoking, dietary intakes 158 
(energy, vitamin D and polyunsaturated fatty) acid as potential confounders. Significance was 159 
set at p < 0.05. 160 
Results 161 
Influences of supplementation on circulation 25(OH)D in relation to the DBP gene 162 
variant  163 
To examine the effect of DBP variant on the serum levels of the total 25-hydroxy vitamin D 164 
after the intervention, subjects were categorized across rs4588 genotypes. The results 165 
demonstrated a significant trend in the distribution of vitamin D status (desirable, sufficiency 166 
and deficiency) among different genotypes at baseline and after supplementation P-trend = 167 
0.03 and 0.008 respectively (Table 1). As shown the serum 25(OH) D response depended on 168 
the SNP in DBP (Table. 1 and 2). Our data revealed that after adjusting for potential 169 
confounders including age, BMI and physical activity, passive smoking, energy intake, 170 
dietary intake of vitamin D and poly-unsaturated fatty acid, sun exposure the SNP rs4588 171 
could modulate response to vitamin D supplementation (p-value of intervention effect <0.001 172 
and p-value SNP=0.03) (Fig. 1). Accordingly, serum 25(OH) D increased in all genotype 173 
groups, but carriers who had the common AA genotype had higher 25-hydroxy vitamin D 174 
concentrations after 9 weeks of intervention. The regression model also indicated that the 175 
probability of rise in serum 25(OH) D in individuals who had homozygous rare genotype GG 176 
was 4.407-fold less than carriers of the common AA genotype (after adjusted for 177 
confounders) (OR=4.407(1.82-8.89), 0.001)  (table 3). The regression analysis was also 178 
significant in unadjusted model (OR=3.72(1.94-7.139),<0.001). Potential confounders were 179 
age, BMI, physical activity and passive smoking, energy intake, dietary intake of vitamin D 180 
and poly-unsaturated fatty acid, sun exposure. 181 
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Influence of supplementation on metabolic profile in DBP variant 182 
Further analysis showed that although fasting blood glucose fell in carriers of common A 183 
allele, it rose in individuals with GG genotype (before intervention 88.7±9.6 mg/dl and after 184 
intervention= 91.04±14.3 mg/dl) (Table 2). Furthermore, serum 25-hydroxy vitamin D 185 
increased in all genotypes after supplementation, and as data showed elevation was more 186 
significant in AA common genotype %469.5(427.1). 187 
Discussion 188 
Influence of supplementation on circulation 25(OH) D in DBP variant 189 
The aim of the current trial study was to examine the response to supplementation with 190 
respect to a genetic variant of the DBP locus in a healthy group of Iranian girl adolescences. 191 
The results demonstrated that this polymorphism was statistically related to serum 25-192 
hydroxy vitamin D at both baseline and follow-up. We found that intake of 50000 IU/D 193 
vitamin D3 per week had beneficial effects on the total 25(OH)D circulation in all genotype 194 
groups. However, the carriers of the common AA genotype were better responders to vitamin 195 
D supplementation on the basis of elevation serum 25(OH)D.  196 
Genome-wide association studies (GWAS) have demonstrated associations between various 197 
single-nucleotide polymorphisms (SNPs) and the vitamin D metabolism pathway with serum 198 
25(OH)D level [18]. Several of these SNPs have been associated with the elevating serum 199 
25(OH)D3  in response to the vitamin D supplementation [10, 19]. In a cohort of Chinese 200 
individuals, it was demonstrated that DBP variants including rs1155563, rs2282679, T436K 201 
and D432E were statistically related to a lower level of serum 25(OH) D3[20]. Similarly, 202 
results of a cross-sectional study on Danish Caucasian population suggested DBP phenotype 203 
as an independent predictor of serum 25(OH)D3  [21]. In two independent European studies, 204 
it was shown that there was a significant association between SNP rs2282679 with 25(OH) 205 
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D3 concentrations [18]. Moreover, Fu et.al examined 436KK in a healthy population, they 206 
also suggested 436KK homozygosity influenced the level of serum 25-hydroxy vitamin D at 207 
baseline and also modified the response to vitamin D3 supplementation [22].  208 
Influence of supplementation on fasting blood glucose in DBP variant 209 
We also showed that fasting blood sugar increased in the carriers of uncommon GG genotype 210 
after intervention by vitamin D supplementation while this parameter was dropped in 211 
individuals who had a common A allele. However, although the variable of “percentage of 212 
change after intervention” was not statistically significant. It appears that clinical outcome in 213 
response to vitamin D supplementation was gene-dependent.  214 
Emerging evidence has reported a relationship between vitamin D supplementation and 215 
clinical diabetes. The functions of vitamin D on the treatment of pre-diabetes and diabetes 216 
through anti-inflammatory mechanisms and improving insulin sensitivity have been proposed 217 
in emerging evidence. Therefore, genetic variants in the DBP gene locus appear to have an 218 
impact on FBG and diabetes. Proteomic investigations have reported DBP as a hepatic acute 219 
phase reactant that in diabetes it would be upregulated [23]. However, the results from 220 
various ethnicities were inconsistent.  Studies on Japanese and Indian population supported 221 
our finding. They revealed that DBP variants influenced fasting plasma insulin levels in 222 
normal glucose tolerance[24, 25]. In Japanese with Gc1S-2 and Gc1S-1S, fasting plasma 223 
insulin was higher than in those who were homozygotes for Gc1F. Furthermore, in a cohort 224 
study by Baier on non-diabetics, results revealed that exon 11 polymorphisms in this locus 225 
were correlated with blood glucose responses to oral glucose; however, they found no 226 
association with fasting glucose plasma and insulin levels [26]. Another study on Hispanic 227 
and Caucasian individuals revealed no associations between DBP variants and levels of 228 
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insulin [27].  Various cohorts and cross sectionals have failed to show a strong association 229 
between DBP and diabetics outcome. 230 
Conclusion 231 
We have found that Gc-rs4588 was could modify responses to high dose vitamin D 232 
supplementation. We also revealed that clinical outcome of supplementation may be gene-233 
related so that in the carriers of the rare homozygous genotype of rs4588, fasting blood 234 
glucose increased after the intervention.  235 
 236 
 237 
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Table 1.  Vitamin D status before and after vitamin D supplementation according to DBP genotypes. 
Vitamin D status 
(N=619) 
AA AG GG 
Baseline Follow-up Baseline Follow-up Baseline Follow-up 
Desirable 25 (6.9) 200 (65.8) 13 (6) 101 (58.4) 1 (2.5) 8 (33.3) 
Sufficiency 27 (7.5) 56 (18.4) 14 (6.5) 33 (19.1) 0 (0) 6 (25) 
deficiency 310 (85.6) 48 (15.8) 189 (87.5) 39 (22.5) 39 (97.5) 10 (41) 
Note: Σ2 test showed a Ptrend of 0.03 at baseline; Ptrend at follow-up is 0.008. Data is presented as frequencies (%). Deficiency: 
Serum 25(OH)D level < 50 nmol/l. Sufficiency: Serum 25(OH) D level between 50 to 75 nmol/l. Desirable: Serum 25(OH)D level 
> 75 nmol/l. 
13 
 
Table 2.  Comparisons of the variables before and after 25-hydroxyvitamin D3 supplementation in 
different genetic modes. 
Variable AA (N=362) AG (N=216) GG (41) 
P-value 
Anthropometric 
BMI (kg/m2) 
Baseline 21.7±3.9 21.9±4.4 21.6±4.0 0.1 
Follow-up 21.4±4.4 21.7±4.4 21.5±4.2 0.12 
Change (%) 0(-4.2) 0(-3.8) 0(-2.7) 0.7 
Blood pressure 
SBP (mmHg) 
Baseline 101.0±12.5 101.3±13.3 100.8±11.9 0.38 
Follow-up 100.4±13.0 100.3±13.3 101.5±10.4 0.57 
Change (%) 0(-11.3) 0(-18.3) 0(-19) 0.8 
DBP(mmHg) 
Baseline 67.9±9.6 67.1±9.7 68.1±11.4 0.1 
Follow-up 64.4±10.8 64.8±10.3 65±10.0 0.6 
Change (%) 0(-20) 0(-22) 0(-23) 0.18 
Lipid profile 
 
Cholesterol 
(mg/dl) 
Baseline 165.1±28.7 162.5±28 156.1±23.1 0.2 
Follow-up 155.6±27.0 152.1±29.7 148.3±16.6 0.4 
Change (%) -6.3(-16) -6.5(-16.2) -6(-17.4) 0.2 
TG (mg/dl) 
Baseline 83.7±36 81.4±34.3 76.3±26.8 0.8 
Follow-up 81.5±35 77.1±32.3 81.7±35 0.1 
HDL(mg/dl) 
Baseline 47.91±8.8 46.8±9 46.5±7.9 0.5 
Follow-up 45.8±8.7 44.5.3±7.8 46.8±8.7 0.4 
Change (%) -4.2(-14.2) -3.2(-18.3) -3.4(-19.7) 0.6 
LDL(mg/dl) 
Baseline 101.1±23.6 101.5±24 96.6±19 0.8 
Follow-up    0.3 
Change (%) -10(-28.7) -14(-22.1) -10.7(-22.4) 0.1 
Serum glucose 
FBG (mg/dl)* 
Baseline 88.3±11.1 86.9±9.8 88.7±9.6 0.1 
Follow-up 86.7±11.3 85.2±11.8 91.04±14.3 0.03 
Change (%) -2.5(-6) -2.1(-4) 0(1.5) 0.2 
Serum metabolite 
Vitamin D** 
(nmol/L) 
Baseline 29.2±26.6 24.1±20.8 15.6±18.7 0.01 
Follow-up 95.6±41.8 83.3±41 63.06±37.5 <0.001 
Change (%) 469.5(427.1) 320.9(433.8) 335.8(530) 0.001 
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Calcium (mg/dl) 
Baseline 9.4±0.5 9.4±0.56 9.0±0.97 0.001 
Follow-up 9.7±0.5 9.7±0.5 9.7±0.5 0.1 
Change (%) 4.4(-0.5) 2.1(8.6) 2.1(9.6) 0.07 
Phosphate 
(mg/dl) 
Baseline 3.9±0.40 3.8±0.40 3.8±0.40 0.1 
Follow-up 4.1±0.40 4.0±0.40 4.0±0.38 0.5 
Change (%) 5(12.4) 5(13.4) 4.8(13.8) 0.6 
Creatinine 
(mg/dl) 
Baseline 0.65±0.09 0.63±0.09 0.6±0.1 0.5 
Follow-up 0.69±0.08 0.7±0.07 0.68±0.08 0.4 
Change (%) 14.3(16.7) 14.3(16.7) 0 (16.7) 0.6 
Abbreviation: BMI, body mass index; SBP, systolic blood pressure, DBP, diastolic blood pressure; TG, triglyceride;  HDL, high 
density lipoprotein; LDL, low density lipoprotein; FBG, fasting blood glucose; WBC, white blood cell; Hs-CRP, high sensitivity 
reactive protein. Note: Change = ((Follow up – Baseline)/Baseline)/100;  
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Fig.2.Serum 25(OH) D stratified by a polymorphism in Gc gene-rs4588. Values are means ± std. Repeated measures 342 
adjusted for multiple comparisons by Bonferroni test for serum 25(OH) D3 levels. Covariates used: age, BMI and 343 
physical activity, passive smoking, energy intake, dietary intake of vitamin D and poly-unsaturated fatty acid, sun 344 
exposure. 345 
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Table 3. Association of GC variant- rs4588 with circulation levels of 25(OH) D (N=619). 
Genotype AA AG GG 
                                                OR (95% CI), p-value 
Model.1 Reference 1.44(0.975-2.14), 0.07 3.72(1.94-7.139),<0.001 
Model.2 Reference 1.48(0.9-2.2), 0.06 3.80(1.95-7.39),<0.001 
Mdel.3 Reference 1.40(0.19-2.3), 0.10 4.40(1.82-8.89), 0.001 
Model. 1: adjusted for no confounder. 
Model.2: adjusted for age, BMI, physical activity, sun protection, passive smoking. 
Model.3: adjusted for both confounders in model 2 and vitamin D intake and dietary poly unsaturated fatty acid. 
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 380 
Fig.1. Cohort flowchart 381 
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 383 
 384 
Fig.2.Serum 25(OH) D stratified by a polymorphism in Gc gene-rs4588. Values are means ± std. Repeated measures 385 
adjusted for multiple comparisons by Bonferroni test for serum 25(OH) D levels. Covariates used: age, BMI and 386 
physical activity, passive smoking sun exposure, vitamin D intake and dietary poly unsaturated fatty acid. 387 
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